GH Research PLC (NASDAQ:GHRS - Get Free Report) traded up 3.3% on Monday . The company traded as high as $8.00 and last traded at $7.90. 18,973 shares traded hands during trading, a decline of 76% from the average session volume of 79,986 shares. The stock had previously closed at $7.65.
Wall Street Analyst Weigh In
GHRS has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of GH Research in a research report on Thursday, September 5th. JMP Securities reaffirmed a "market outperform" rating and issued a $39.00 price target on shares of GH Research in a report on Wednesday, September 4th.
Read Our Latest Report on GH Research
GH Research Stock Up 5.4 %
The company has a 50 day simple moving average of $8.27 and a 200-day simple moving average of $10.61. The stock has a market cap of $419.35 million, a price-to-earnings ratio of -13.00 and a beta of 0.79.
GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. On average, equities research analysts expect that GH Research PLC will post -0.89 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. raised its stake in GH Research PLC (NASDAQ:GHRS - Free Report) by 11.9% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,251,714 shares of the company's stock after acquiring an additional 664,381 shares during the period. RA Capital Management L.P. owned 12.02% of GH Research worth $66,643,000 as of its most recent SEC filing. Institutional investors and hedge funds own 56.90% of the company's stock.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Read More
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
